Classification, pathophysiology, and etiology of tricuspid valve disorders.
Category
Type/Subtype
Description
Classification
TR
The most common right-sided valvular lesion in adults, physiological trace to mild TR, is often normal [17, 18].
Classification
Primary regurgitation
Caused by intrinsic abnormalities such as congenital defects, infective endocarditis, or rheumatic disease [19].
Classification
Secondary (functional) regurgitation
Due to RV dilation or pulmonary hypertension, which pulls valve leaflets apart, impairing closure [19].
Classification
TS
Thickened or fused leaflets restrict forward blood flow from RA to RV, often caused by rheumatic disease, carcinoid syndrome, or congenital anomalies [2].
Pathophysiology
Annular dilation and leaflet tethering
The TA is more likely to dilate with RV enlargement. Annular dilation and leaflet tethering (from RA/RV dilation) impair coaptation and worsen TR [19–21].
Pathophysiology
Septal annulus dynamics
The septal portion of the TA remains relatively fixed and is less affected by RV dilation, contributing to asymmetric distortion [19–21].
Etiology
Heart failure and left-sided disease
TR usually results from RV dilation caused by pulmonary hypertension, often secondary to left-sided heart disease or lung conditions like emphysema [3].
Etiology
Other causes of TR
Includes trauma, infective endocarditis, rheumatic heart disease, and congenital defects [3].
Etiology
Device-related TR
ICD or pacemaker leads can interfere with leaflet coaptation or cause fibrosis and tethering, leading to TR. Often diagnosed late [22].
Etiology
Role of imaging
Transesophageal echocardiography and 3DE are essential for detection and grading of device-related TR [22].
BDA, FB, HSG, HWN, HTA, WT, YTT, AK, MUA, EHH, IK, and MU: Conceptualization, Writing—original draft, Investigation. All authors critically revised the manuscript for important intellectual content, approved the final version, and agreed to be accountable for all aspects of the work.
Conflicts of interest
The authors declare that they have no competing interests.
Ethical approval
Not applicable. This article does not involve any studies with human participants or animals performed by any of the authors.
Consent to participate
Not applicable.
Consent to publication
Not applicable.
Availability of data and materials
Not applicable. No new datasets were generated or analysed for this review.
Funding
The authors received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors for the preparation of this manuscript.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Ansari Y, Raja A, Raja S, Ali SME, Ali F, Noor I, et al. Investigating mortality trends and disparities in tricuspid valve disorder: a U.S. nationwide study from 1999 to 2023.BMC Cardiovasc Disord. 2025;25:208. [DOI] [PubMed] [PMC]
Davidson LJ, Tang GHL, Ho EC, Fudim M, Frisoli T, Camaj A, et al. The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation. 2024;149:e1223–38. [DOI] [PubMed]
Messika-Zeitoun D, Verta P, Gregson J, Pocock SJ, Boero I, Feldman TE, et al. Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis.Eur J Heart Fail. 2020;22:1803–13. [DOI] [PubMed]
Shariff M, Kumar A, Hirji SA, Majmundar M, Adalja D, Doshi R. Ten Years Mortality Trends of Tricuspid Regurgitation in the United States, 2008 to 2018.Am J Cardiol. 2021;140:156–7. [DOI] [PubMed]
Jain A, Gebhardt B, Subramani S, Mehrotra M, Gaber M, Ramakrishna H. Tricuspid Regurgitation: Analysis of Outcomes and Risk Assessment.J Cardiothorac Vasc Anesth. 2024;38:1397–408. [DOI] [PubMed]
Gerçek M, Rudolph V. Secondary Tricuspid Regurgitation: Pathophysiology, Incidence and Prognosis.Front Cardiovasc Med. 2021;8:701243. [DOI] [PubMed] [PMC]
Kolte D, Kennedy KF, Passeri JJ, Inglessis I, Elmariah S. Temporal Trends in Prevalence of Tricuspid Valve Disease in Hospitalized Patients in the United States.Am J Cardiol. 2020;125:1879–83. [DOI] [PubMed]
Vemulapalli S, Kerr MSD, Roberts GJ, Prillinger JB, Meduri CU, McCarthy P. Tricuspid valve disease prevalence and the impact of tricuspid valve surgery on cardiovascular events and hospital resource use in medicare beneficiaries.Am Heart J. 2022;245:100–9. [DOI] [PubMed]
Barbero C, Pocar M, Brenna D, Costamagna A, Aloi V, Capozza C, et al. Surgical Treatment for Isolated Tricuspid Valve Disease: A Less Invasive Approach for Better Outcomes.J Clin Med. 2024;13:3144. [DOI] [PubMed] [PMC]
Chick W, Alkhalil M, Egred M, Gorog DA, Edwards R, Das R, et al. A Systematic Review and Meta-Analysis of the Clinical Outcomes of Isolated Tricuspid Valve Surgery.Am J Cardiol. 2023;203:414–26. [DOI] [PubMed]
Rodés-Cabau J, Taramasso M, O’Gara PT. Diagnosis and treatment of tricuspid valve disease: current and future perspectives.Lancet. 2016;388:2431–42. [DOI] [PubMed]
Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM, et al. National Trends and Outcomes in Isolated Tricuspid Valve Surgery.J Am Coll Cardiol. 2017;70:2953–60. [DOI] [PubMed]
Hahn RT, George I, Kodali SK, Nazif T, Khalique OK, Akkoc D, et al. Early Single-Site Experience With Transcatheter Tricuspid Valve Replacement.JACC Cardiovasc Imaging. 2019;12:416–29. [DOI] [PubMed]
Members WC; Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.J Am Coll Cardiol. 2021;77:e25–197. [DOI] [PubMed]
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Sundt TM 3rd, Guyton RA, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2014;63:2438–88. [DOI] [PubMed]
Hung J. The pathogenesis of functional tricuspid regurgitation.Semin Thorac Cardiovasc Surg. 2010;22:76–8. [DOI] [PubMed]
Badano LP, Muraru D, Enriquez-Sarano M. Assessment of functional tricuspid regurgitation.Eur Heart J. 2013;34:1875–85. [DOI] [PubMed]
Yucel E, Bertrand PB, Churchill JL, Namasivayam M. The tricuspid valve in review: anatomy, pathophysiology and echocardiographic assessment with focus on functional tricuspid regurgitation.J Thorac Dis. 2020;12:2945–54. [DOI] [PubMed] [PMC]
Mahmood F, Kim H, Chaudary B, Bergman R, Matyal R, Gerstle J, et al. Tricuspid annular geometry: a three-dimensional transesophageal echocardiographic study.J Cardiothorac Vasc Anesth. 2013;27:639–46. [DOI] [PubMed] [PMC]
Dahou A, Levin D, Reisman M, Hahn RT. Anatomy and Physiology of the Tricuspid Valve.JACC Cardiovasc Imaging. 2019;12:458–68. [DOI] [PubMed]
DesJardin JT, Chikwe J, Hahn RT, Hung JW, Delling FN. Sex Differences and Similarities in Valvular Heart Disease.Circ Res. 2022;130:455–73. [DOI] [PubMed] [PMC]
Tersalvi G, Gaiero L, Capriolo M, Cristoforetti Y, Salizzoni S, Senatore G, et al. Sex Differences in Epidemiology, Morphology, Mechanisms, and Treatment of Mitral Valve Regurgitation.Medicina (Kaunas). 2023;59:1017. [DOI] [PubMed] [PMC]
Scotti A, Sturla M, Echarte-Morales J, Ho EC, Millin A, Coisne A, et al. Burden of Valvular Heart Diseases in a Racially and Ethnically Diverse Population: The Bronx-Valve Registry.J Am Heart Assoc. 2025;14:e035378. [DOI] [PubMed] [PMC]
Badano LP, Tomaselli M, Muraru D, Galloo X, Li CHP, Marsan NA. Advances in the Assessment of Patients With Tricuspid Regurgitation: A State-of-the-Art Review on the Echocardiographic Evaluation Before and After Tricuspid Valve Interventions.J Am Soc Echocardiogr. 2024;37:1083–102. [DOI] [PubMed]
Lang RM, Mor-Avi V, Sugeng L, Nieman PS, Sahn DJ. Three-dimensional echocardiography: the benefits of the additional dimension.J Am Coll Cardiol. 2006;48:2053–69. [DOI] [PubMed]
Blusztein DI, Hahn RT. New therapeutic approach for tricuspid regurgitation: Transcatheter tricuspid valve replacement or repair.Front Cardiovasc Med. 2023;10:1080101. [DOI] [PubMed] [PMC]
Khalique OK, Jelnin V, Hueske A, Lawlor M, Leon MB, Kodali SK, et al. Right Heart Morphology of Candidate Patients for Transcatheter Tricuspid Valve Interventions.Cardiovasc Eng Technol. 2022;13:573–89. [DOI] [PubMed] [PMC]
Sala A, Hahn RT, Kodali SK, Mack MJ, Maisano F. Tricuspid Valve Regurgitation: Current Understanding and Novel Treatment Options.J Soc Cardiovasc Angiogr Interv. 2023;2:101041. [DOI] [PubMed] [PMC]
Maisano F, Hahn R, Sorajja P, Praz F, Lurz P. Transcatheter treatment of the tricuspid valve: current status and perspectives.Eur Heart J. 2024;45:876–94. [DOI] [PubMed]
Bursi F, Enriquez-Sarano M. Global and local view of tricuspid regurgitation: a call for action.Pol Arch Intern Med. 2024;134:16818. [DOI] [PubMed]
von Bardeleben RS, Lurz P, Sorajja P, Ruf T, Hausleiter J, Sitges M, et al.; TRILUMINATE Trial Investigators. Two-Year Outcomes for Tricuspid Repair With a Transcatheter Edge-to-Edge Valve Repair From the Transatlantic TRILUMINATE Trial.Circ Cardiovasc Interv. 2023;16:e012888. [DOI] [PubMed]
Ktenopoulos N, Katsaros O, Apostolos A, Drakopoulou M, Tsigkas G, Tsioufis C, et al. Emerging Transcatheter Therapies for Valvular Heart Disease: Focus on Mitral and Tricuspid Valve Procedures.Life (Basel). 2024;14:842. [DOI] [PubMed] [PMC]
Lancellotti P, Pibarot P, Chambers J, Canna GL, Pepi M, Dulgheru R, et al.; Scientific Document Committee of the European Association of Cardiovascular Imaging. Multi-modality imaging assessment of native valvular regurgitation: an EACVI and ESC council of valvular heart disease position paper.Eur Heart J Cardiovasc Imaging. 2022;23:e171–232. [DOI] [PubMed]
Hahn RT, Makkar R, Thourani VH, Makar M, Sharma RP, Haeffele C, et al.; TRISCEND II Trial Investigators. Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.N Engl J Med. 2025;392:115–26. [DOI] [PubMed]
Abdelbar A, Kenawy A, Zacharias J. Minimally invasive tricuspid valve surgery.J Thorac Dis. 2021;13:1982–92. [DOI] [PubMed] [PMC]
Wilde N, Silaschi M, Alirezaei H, Vogelhuber J, Sugiura A, Tanaka T, et al. Transcatheter edge-to-edge valve repair versus minimally invasive beating-heart surgery of the tricuspid valve: an observational study.EuroIntervention. 2023;19:659–61. [DOI] [PubMed] [PMC]
Dreyfus J, Ghalem N, Garbarz E, Cimadevilla C, Nataf P, Vahanian A, et al. Timing of Referral of Patients With Severe Isolated Tricuspid Valve Regurgitation to Surgeons (from a French Nationwide Database).Am J Cardiol. 2018;122:323–6. [DOI] [PubMed]
Kilic A, Saha-Chaudhuri P, Rankin JS, Conte JV. Trends and outcomes of tricuspid valve surgery in North America: an analysis of more than 50,000 patients from the Society of Thoracic Surgeons database.Ann Thorac Surg. 2013;96:1546–52. [DOI] [PubMed]
Axtell AL, Bhambhani V, Moonsamy P, Healy EW, Picard MH, Sundt TM 3rd, et al. Surgery Does Not Improve Survival in Patients With Isolated Severe Tricuspid Regurgitation.J Am Coll Cardiol. 2019;74:715–25. [DOI] [PubMed] [PMC]
Alnajar A, Chatterjee S, Olive JK, Kaymakci MS, Gray L, Gray Z, et al. Outcomes of minimally invasive isolated tricuspid valve repair and replacement through right mini-thoracotomy.JTCVS Open. 2023;17:98–110. [DOI] [PubMed] [PMC]
Arafat AA, Alghosoon H, Alghamdi R, Albabtain MA, Ismail H, Adam AI, et al. Comparison of short- and long-term outcomes between isolated and concomitant tricuspid valve surgery.Cardiothorac Surg. 2024;32:24. [DOI]
Shimoda TM, Ueyama HA, Miyamoto Y, Watanabe A, Gotanda H, Elmariah S, et al. Outcomes of isolated tricuspid replacement versus repair among older patients with tricuspid regurgitation in the United States.JTCVS Open. 2024;24:127–46. [DOI] [PubMed] [PMC]
Altarabsheh SE, Crestanello JA, Saran N, Daly RC, Dearani JA, Greason KL, et al. Impact of pulmonary hypertension and right ventricular function on outcomes of isolated tricuspid valve surgery.JTCVS Open. 2025;24:115–26. [DOI] [PubMed] [PMC]
Ambrosino M, Sangoi M, Monzer N, Irving B, Fiorilli P, Khazan B, et al. Tricuspid Regurgitation: A Review of Current Interventional Management.J Am Heart Assoc. 2024;13:e032999. [DOI] [PubMed] [PMC]
Harb SC, Kapadia SR. Patients’ selection for transcatheter tricuspid valve interventions: Who will benefit?Prog Cardiovasc Dis. 2019;62:467–72. [DOI] [PubMed]
Coisne A, Lancellotti P, Habib G, Garbi M, Dahl JS, Barbanti M, et al. ACC/AHA and ESC/EACTS Guidelines for the Management of Valvular Heart Diseases: JACC Guideline Comparison.J Am Coll Cardiol. 2023;82:721–34. [DOI] [PubMed]
Inanc IH, Cilingiroglu M, Iliescu C, NInios V, Matar F, Ates I, et al. Comparison of American and European Guidelines for the Management of Patients With Valvular Heart Disease.Cardiovasc Revasc Med. 2023;47:76–85. [DOI] [PubMed]
Gupta R, Abdul-Rahman T, Gaur A, Roy P, Thaalibi HI, Kundu M, et al. Transcatheter Tricuspid Valve Interventions: a Narrative Review of Current Evidence and Future Directions.Curr Treat Options Cardio Med. 2025;27:53. [DOI]